HEARTSEED
11.6.2021 09:02:11 CEST | Business Wire | Press release
Heartseed , a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.
New investors are UTokyo Innovation Platform Co. (UTokyo IPC), Medical Incubator Japan, Keio Innovation Initiative (KII), and Sumitomo Mitsui Trust Investment. Among the existing investors, SBI Group, Nissay Capital, SMBC Capital, Medipal Holdings, and Itochu Chemical Frontier participated in this round.
Heartseed will use the new funds to accelerate the initiation of global clinical trial of HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan. Additionally, Heartseed will also examine a less invasive administration such as transendocardial injection using a catheter.
“Heartseed has made a strong progress in our research and development of our cardiac remuscularization therapy, as proved by the clearance of clinical trial application of Phase I/II LAPiS Study by the Japanese Pharmaceutical and Medical Agency and many awards we received.” said Professor. Keiichi Fukuda, co-founder and CEO at Heartseed. “The commitment from both new and existing investors in this round is a strong validation of our technology and strategic vision. With their support, we look forward to accelerating our development to deliver potentially curative therapy for heart failure across the globe.”
About HS-001
Heartseed's lead pipeline, HS-001, is allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for safe and efficient administration of the spheroids into the myocardial layer of the heart.
The expected mechanism of action is that the transplanted cardiomyocytes electrically couple with the patient's myocardium to improve cardiac output by remuscularization, and secretion of angiogenic factors to form new blood vessels around the transplant site (neovascularization).
The review of the Clinical Trial Application of a phase I/II clinical trial (LAPiS Study) evaluating the safety and efficacy of HS-001 for the treatment of heart failure caused by ischemic heart disease in Japan was successfully completed in March 2021 by Japan's Pharmaceutical and Medical Devices Agency.
For details: http://www.heartseed.jp/en/index.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20210611005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TradingHub Secures Strategic Investment From Nordic Capital to Accelerate Next Phase of Growth16.3.2026 17:00:00 CET | Press release
TradingHub, a leading provider of trade surveillance technology for global financial institutions, has agreed to partner with Nordic Capital which will become the company’s majority shareholder. The investment marks a significant milestone in TradingHub’s journey and provides strong backing to support the company’s continued growth and innovation. Existing investor Summit Partners and TradingHub’s co-founder Neil Walker will continue to hold minority positions in the company following the close of the transaction. With the support of Nordic Capital, TradingHub will accelerate its expansion across global markets while continuing to invest in the development of its trade surveillance platform. The company plans to further strengthen its capabilities across asset classes, including equities, and continue its expansion into new markets and geographies. Founded in 2010 and today operating from offices in London, Toronto, Singapore and Sydney, TradingHub has built a highly differentiated tec
Madinah Hosts Third Umrah and Ziyarah Forum with Strong International Participation16.3.2026 16:10:00 CET | Press release
The third edition of the Umrah and Ziyarah Forum will commence in Madinah on Monday, March 30, 2026. The forum is organized by the Ministry of Hajj and Umrah, in partnership with the Pilgrim Experience Program, at the King Salman International Convention Center, with wide participation from business leaders, decision-makers, and specialists in the Umrah and Ziyarah services ecosystem from around the world to exchange expertise and explore ways to further enrich the experience of the Guests of Allah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316471639/en/ Madinah Hosts Third Umrah and Ziyarah Forum with Strong International Participation (Photo: AETOSWire) This year’s edition builds on the success of the forum's previous editions, reaffirming its position as a global platform for advancing the Umrah and Ziyarah services ecosystem. It focuses on enhancing services for Umrah performers and visitors, in line with the gro
Capcom’s Official Street Fighter 6 World Championship Tournaments Attract Record-high 20,000 Attendees16.3.2026 14:00:00 CET | Press release
– Capcom aims to accelerate growth of the global competitive scene with a larger total prize pool of over $2.1 million in the upcoming 2026 season – Capcom Co., Ltd. (TOKYO:9697) today announced that Capcom Cup 12 and Street Fighter League: World Championship 2025, its official world championship tournaments to determine the top Street Fighter 6 competitors, which were held at Ryogoku Kokugikan Arena from March 11-15, achieved a record-high of 20,000 attendees, concluding with great success. At Capcom Cup 12, which features matches against individual players, SAHARA (21 years old), who is a first‑year professional player, claimed the championship title in his debut appearance, while in the team-based competition Street Fighter League: World Championship 2025, Japanese representatives REJECT were the winning team. Capcom additionally announced that it will hold next season’s Capcom Cup 13 and Street Fighter League: World Championship 2026 at Ryogoku Kokugikan Arena. Furthermore, the com
Capcom’s Resident Evil Requiem Sales Exceed 6 Million Units!16.3.2026 14:00:00 CET | Press release
– Capcom also plans to release additional game content – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, now exceed 6 million units, which is the fastest that a title in the series has reached this milestone. Resident Evil Requiem is the latest installment in the Resident Evil series, which offers photorealistic visuals and a deep sense of immersion. Players can enjoy the elevated essence of the survival horror experience by the interplay between intense fear and exhilarating action, made possible by two protagonists. Going forward, Capcom plans to implement several measures, such as ongoing support and additional game content, so players can continue to enjoy the title longer. In addition, the Resident Evil series will celebrate its 30th anniversary on March 22,2026. Capcom is readying various plans for this anniversary to delight series fans, such as a collaboration between Universal Studios Japan and Residen
Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware16.3.2026 14:00:00 CET | Press release
Advances one of Japan’s leading public-private partnership initiatives for fusion commercialization with NIFS and industrial partners Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/ Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (ene
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom